Magnesium Glycinate
TL;DR
Magnesium glycinate (bisglycinate) is a well-absorbed, GI-friendly magnesium form with meaningful evidence for sleep quality and autonomic (HRV) signals, but no direct cognitive effect and no specific DOMS benefit. It is NOT Mg L-threonate — do not conflate the two. The glycinate form does NOT cross the blood-brain barrier in pharmacologically relevant concentrations; any CNS effect is indirect via improved systemic Mg. For Ben: 250 mg elemental (~1,775 mg compound) at bedtime, start low, assess at 4 weeks minimum.
Why it matters for Vitals
Ben: 65 kg, Phuket (~7°N), daily training, 3 days post wrist injury, Retatrutide week 4, GHK-Cu 1 mg/day, Creatine starting.
Elevated magnesium requirement
- Daily training → athletes need ~10–20% above sedentary RDA (~440–480 mg elemental/day vs 400–420 mg)
- Phuket heat/sweat → trained individuals in hot/humid environments lose 10–30 mg Mg per liter of sweat; 1–2 L daily sweat loss = 10–60 mg additional daily Mg loss
- Retatrutide caloric restriction → lower dietary Mg intake + GI malabsorption risk → elevated deficiency risk
- Daily training → high recovery demand → sleep is the primary recovery lever; Mg glycinate has the strongest RCT support for sleep quality among Mg forms
Glycinate form choice
Best GI tolerance among organic Mg salts. Glycine co-transported, higher absorption than oxide/citrate. Glycine itself promotes sleep onset via NMDA modulation — additive sleep benefit.
What it does NOT do
- Does NOT cross the blood-brain barrier in pharmacologically relevant concentrations (unlike Mg L-threonate/Magtein)
- Does NOT improve wearable-measured sleep stages (REM %, deep sleep %)
- Does NOT prevent exercise-associated muscle cramps (Cochrane 2020: no RCT evidence for oral Mg)
- Does NOT have direct ergogenic/performance effect in Mg-replete athletes
Key Facts
| Elemental Mg content | 14.1% by mass (Mg(C₂H₅NO₂)₂ MW 174.42 g/mol) |
| 250 mg elemental | ≈ 1,775 mg compound (2 × 888 mg capsules) |
| Bioavailability | ~40–50% (organic chelate); far superior to oxide (~4%) |
| Absorption pathway | Dipeptide transporter (PepT1) — absorbed as intact chelate; paracellular diffusion for ionic Mg²⁺ |
| GI tolerance | Best of all Mg forms; far superior to oxide and citrate |
| BBB crossing | ❌ Does NOT cross BBB in pharmacologically relevant amounts |
| Glycine co-benefit | ~760 mg glycine per 250 mg elemental dose; promotes sleep onset (~17 min SOL reduction) |
| Start dose | 125 mg elemental (week 1) → 250 mg elemental standard |
| Timing | 30–60 minutes before bed; empty stomach or small snack |
| Form to avoid | Buffered glycinate (often contains Mg oxide filler); Mg L-threonate (different indication) |
Mechanism Summary
Magnesium (systemic)
Magnesium is a cofactor for 600+ enzymatic reactions:
- Na/K-ATPase — cellular membrane potential, muscle function
- ATP synthesis — mitochondrial energy production
- Protein synthesis — muscle repair
- NMDA receptor modulation — Mg²⁺ blocks the NMDA calcium channel at rest; deficiency lowers the activation threshold → neuronal hyperexcitability and sleep disruption
- GABAergic activity — Mg supports GABA function, promoting sleep onset
- Calcium antagonism — Mg competes with calcium at voltage-gated channels; reduces catecholamine (adrenaline/noradrenaline) release → lower sympathetic tone → reduced cortisol response to stress
- Melatonin synthesis — Mg involved in serotonin → melatonin conversion (indirect pathway)
Glycine co-benefit
At 250 mg elemental Mg as glycinate, Ben gets ~760 mg glycine. Glycine independently acts on NMDA/AMPA receptors and somnogenic pathways, reducing sleep onset latency by ~17 minutes in clinical trials.
Critical distinction: Glycinate ≠ L-Threonate
Mg glycinate = systemic Mg repletion + glycine sleep benefit. It does NOT elevate brain/CSF magnesium.
The glycine chelate is absorbed enterically via dipeptide transporters (PepT1/Pept2) into the bloodstream. Magnesium is released systemically. The glycinate complex does not cross the blood-brain barrier in pharmacologically relevant concentrations. Any CNS Mg elevation from oral glycinate is indirect (via improved systemic Mg → possible modest BBB transport of ionic Mg²⁺ over days-to-weeks).
→ For direct brain/CSF Mg elevation and cognitive effects, Mg L-threonate (Magtein®) is required — it is the only form with demonstrated brain/CSF magnesium elevation in humans (animal BBB studies + human CSF pilot data). This is a fundamentally different compound with a different indication.
What the Current Evidence Suggests
Strong evidence
| Claim | Evidence | Verdict |
|---|---|---|
| HRV improvement (SDNN, pNN50, rMSSD) with Mg glycinate/bisglycinate | 3+ RCTs; Wienecke 2016 (n=100, 90d); Altimiras 2025 Magtein (n=100, Oura); Nielsen 2010 bis-glycinate (n~30) | ✅ Supported |
| Subjective sleep quality improvement | Bisglycinate RCT n=155 (PMC12412596, 2025): ISI reduction −3.9 vs −2.3 placebo, p=0.049, Cohen’s d=0.2 | ✅ Supported |
| GI tolerance superior to oxide and citrate | Cross-form comparative evidence | ✅ Supported |
| RHR reduction (−3 to −5 bpm over 6+ weeks) | Altimiras 2025 Oura (Magtein, p=0.030); consistent direction in Wienecke | ✅ Supported |
Moderate evidence
| Claim | Evidence | Verdict |
|---|---|---|
| Cortisol reduction in stressed/Mg-deficient populations | Meta-analyses; NIH mechanistic review (NBK507250); direct cortisol RCTs limited | ⚠️ Supported (indirect) |
| Blood pressure reduction in middle-aged/older adults with elevated baseline | NCT03688503 (n=59, 480 mg glycinate, 12 wks): −7 to −8 mmHg systolic vs placebo | ⚠️ Supported (age/dose-dependent) |
| Sleep onset latency reduction (~17 min) | Dovepress/NSS 2025 mechanism review; glycine sleep trials; indirect for Mg glycinate specifically | ⚠️ Supported (via glycine moiety) |
Null findings
| Claim | Evidence | Verdict |
|---|---|---|
| No improvement in wearable-measured sleep stage metrics (REM %, deep sleep %) | Altimiras 2025: HRV improved but sleep stages unchanged (Oura Ring) | ❌ Not supported |
| No direct DOMS/cramp benefit from oral Mg glycinate | Cochrane 2020 (exercise cramps): no RCT evidence for oral Mg | ❌ Not supported |
| No direct ergogenic/performance effect | Systematic reviews in Mg-replete athletes | ❌ Not supported |
| Blood pressure effect in young healthy adults | NCT03688503: BP not reduced in younger cohort | ❌ Null for normotensive young adults |
| Mg glycinate crosses BBB | Disproven for significant CNS elevation | ❌ Not supported |
Form comparison
| Form | Bioavailability | BBB Crossing | Best For |
|---|---|---|---|
| Glycinate/Bisglycinate | ~40–50% | ❌ No | Sleep, autonomic/HRV, systemic Mg repletion, GI-sensitive |
| Citrate | ~30–40% | ❌ No | General Mg repletion, cost-effective |
| L-Threonate (Magtein®) | Moderate | ✅ Yes — demonstrated | Cognitive enhancement only |
| Oxide | ~4% (poor) | ❌ No | Laxative; not recommended for repletion |
Wearable / Biometric Signals
Primary signal: HRV (SDNN)
Magnesium glycinate’s strongest and most consistent wearable signal is HRV improvement via parasympathetic uplift.
- Expected effect: Moderate SDNN/HRV increase over 4–12 weeks
- Key studies: Wienecke 2016 (pNN50 ↑, LF:HF ↓, stress index ↓, 100 pts/90d); Altimiras 2025 (HRV ↑ p=0.036)
- Timeline: 4 weeks (early signal) → 6 weeks (robust HRV/RHR changes) → 12+ weeks (full autonomic rebalancing)
- Confidence: moderate
Secondary signal: Resting Heart Rate
- Expected effect: Small-to-moderate RHR reduction (−3 to −5 bpm over 6+ weeks)
- Key study: Altimiras 2025 Oura (RHR ↓ p=0.030)
- Confidence: moderate
What will NOT show on wearables
- Sleep stages (REM %, deep sleep %): Do NOT expect these to improve reliably. Altimiras 2025: HRV and RHR improved significantly but sleep stage metrics were unchanged on Oura Ring. This is the most important wearable-specific finding for Mg glycinate.
- Sleep efficiency: Small/weak if any change on objective wearable metrics
- Cortisol: Not directly measured by wearables; inferred from HRV patterns
VitalsSync Flags
| Flag | Trigger | Recommended Action |
|---|---|---|
MAG_GLYCINATE_HRV_BOOST | HRV increases >15% within 7–28 days without training change | Flag Mg as cause; apply 4-week settling window before re-baselining |
MAG_GLYCINATE_NULL_SLEEP_STAGES | Subjective sleep better; wearable stages unchanged | Educate: “Mg improves autonomic recovery without changing sleep architecture numbers” |
MAG_GLYCINATE_RHR_DROP | RHR drops >3–5 bpm over 6+ weeks | Treat as legitimate parasympathetic benefit |
Do NOT suppress HRV signals when magnesium is active. These are genuine physiological improvements. Contextualize rather than exclude from composite recovery scores.
Stack Integration
With Retatrutide
- Retatrutide reduces caloric intake → lower dietary Mg → elevated deficiency risk
- Retatrutide GI side effects (nausea, diarrhea) → malabsorption and Mg losses
- Rapid weight loss → catabolism of lean tissue → increased urinary Mg excretion
- No direct pharmacokinetic interaction
Mg may support Retatrutide protocol:
- Improved sleep → better adherence and training consistency
- Cortisol reduction → supports body composition goals
- HOMA-IR improvement → complementary insulin sensitization
Action: No dose adjustment needed. Monitor for additive GI effects (both can cause loose stools). If GI upset, separate doses AM/PM. Ben’s active weight-loss phase = higher Mg deficiency risk = more important to supplement.
With GHK-Cu
- No direct or theoretical interaction identified
- Separate injectable GHK-Cu from oral Mg glycinate by 30–60 minutes if using both; no need to separate topical GHK-Cu
With Creatine
- No direct or theoretical interaction
- Both well-tolerated chronically
- Creatine may mildly affect renal Mg handling but not clinically significant
- No timing or dosing adjustments needed
With Phuket heat/sweat
- Trained individuals in hot/humid environments lose 10–30 mg Mg per liter of sweat
- At 1–2 L daily sweat loss: 10–60 mg additional Mg loss
- At 250 mg elemental/day oral supplementation: Ben may be covering total requirement (dietary ~300–350 mg + sweat losses)
- On extreme heat training days: Consider adding 50–100 mg elemental Mg or ensuring dietary Mg is adequate
Protocol
Dose
| Target | Elemental Mg | Compound (glycinate) | Capsules (typical 888 mg cap) |
|---|---|---|---|
| Start low (week 1) | 125 mg | ~890 mg | 1 cap |
| Standard | 250 mg | ~1,775 mg | 2 caps |
| Maximum (if needed) | 350 mg | ~2,485 mg | 2–3 caps |
Timing
- 30–60 minutes before bed, empty stomach or with small snack
- Rationale: synchronizes with circadian cortisol nadir; glycine component promotes sleep onset
- Not recommended: Within 2 hours of tetracycline/fluoroquinolone antibiotics or bisphosphonates
Duration before assessment
- 4 weeks minimum — consistent with n=155 bisglycinate RCT protocol
- 8 weeks for cortisol confirmation (meta-analyses used ≥8 weeks)
- 6-week HRV re-baseline window before comparing wearable metrics
Form notes
- Use magnesium bisglycinate or magnesium glycinate — avoid “buffered glycinate” (often contains Mg oxide filler)
- Avoid products listing magnesium oxide as primary ingredient
- Magtein (Mg L-threonate) is a different form — not needed for Ben’s sleep/cortisol goals; glycinate is appropriate
- Look for third-party testing (NSF, USP, ConsumerLab)
Long-term
- No tolerance or dependency; no mandatory cycling
- Reassess at 3 months: check sMg/RBC Mg, renal function, GI tolerance
- Can stop abruptly with no rebound effect
Risks and Uncertainties
GI tolerance
- Glycinate is the best-tolerated Mg form — far superior to oxide and citrate
- Most common adverse effect: loose stools / diarrhea at doses >300–400 mg elemental
- Management: Split dose; reduce temporarily; take with food
Renal caution
- Mg is renally excreted; impaired renal function (eGFR <60) → hypermagnesemia risk
- Standard protocol (250 mg elemental/day) is safe with normal renal function
- eGFR <30: Do not supplement without physician supervision
- eGFR 30–59: Reduce to 125–200 mg elemental/day; monitor sMg
Hypermagnesemia signs (stop immediately if present)
Lethargy, bradycardia, hypotension, absent DTRs, respiratory depression — urgent medical attention
Drug Interactions
| Drug Class | Interaction | Action |
|---|---|---|
| Fluoroquinolone antibiotics | Mg chelates drug; severe reduction in absorption | Separate by ≥2 hours AFTER antibiotic dose |
| Tetracycline antibiotics | Same as above | Same as above |
| Bisphosphonates | Mg reduces absorption | Separate by ≥2 hours |
| Digoxin | Narrow therapeutic index; ensure normal sMg | Monitor sMg; physician consultation |
| Levothyroxine | Mg reduces absorption | Separate by ≥4 hours |
| PPIs | May reduce Mg absorption long-term | Check sMg baseline; monitor more closely |
Key Uncertainties
- Apple Watch–specific HRV validation: No RCT has used Apple Watch as primary HRV measurement device. Magtein used Oura Ring; Wienecke used unspecified ECG system. Apple Watch validation is needed.
- Dose-response curve for HRV: Unclear whether 250 mg, 400 mg, or 480 mg elemental produces differential HRV effects.
- Glycine vs Mg contribution: Not disentangled. At 250 mg elemental, Ben gets ~760 mg glycine — within the range studied for standalone glycine sleep doses.
- Wearable-measured sleep architecture with Mg glycinate: Essentially unstudied in trial conditions with device measurement.
- Individual response moderators: Genetics, baseline Mg status, gut microbiome, renal function — poorly characterized for wearable biometric response.
- Serum Mg predicts HRV response: Null — Wienecke 2016 found no change in intracellular Mg concentration despite HRV improvements. RBC Mg is the more accurate intracellular marker.
Related Notes
- Retatrutide — primary stack partner
- GHK-Cu — tissue repair stack partner
- Creatine — ergogenic stack partner
- HRV — biometric signal context
- NMDA receptor — mechanism link (Mg glycinate’s NMDA modulation)